There is usually a big disparity between investors and entrepreneurs regarding the valuation of an early-stage biotech company. How to determine what a company is actually worth? How do funds price the assets? What are the biases from each side? What are the points of negotiation?
November 29th & 30th, 2022
December 7th & 8th, 2022